secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001933414-25-000120
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys prices upsized $250M public offering at $25.50/share
--------------------------------------------------------------

- 9,803,921 shares at $25.50/share; total gross proceeds ~$250M.
- Net proceeds ~$234.7M (~$269.9M if underwriters' option exercised).
- Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
- Underwriters: BofA, Evercore, Goldman, Stifel, Wells Fargo; closing expected Sept 4, 2025.
- Upsized offering reflects strong demand; underwriters have 30-day option for 1.47M additional shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/0001933414-25-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/mlys-20250902.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer